DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:DMCAF
CUSIPN/A
Phone763-496-5454
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees7
Outstanding Shares156,710,000
Market Cap$64.25 million
DiaMedica Therapeutics (OTCMKTS:DMCAF) Frequently Asked Questions
What is DiaMedica Therapeutics' stock symbol?
DiaMedica Therapeutics trades on the OTCMKTS under the ticker symbol "DMCAF."
Who are some of DiaMedica Therapeutics' key competitors?
Some companies that are related to DiaMedica Therapeutics include Axovant Sciences (AXON), Aratana Therapeutics (PETX), Clearside Biomedical (CLSD), Tyme Technologies (TYME), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Ocular Therapeutix (OCUL), Marinus Pharmaceuticals (MRNS), ProQR Therapeutics (PRQR), DURECT (DRRX), Neptune Technologies & Bioressources (NEPT), Protagonist Therapeutics (PTGX), Teligent (TLGT), Chimerix (CMRX), Kamada (KMDA) and Aeglea Bio Therapeutics (AGLE).
Who are DiaMedica Therapeutics' key executives?
DiaMedica Therapeutics' management team includes the folowing people:
- Mr. Rick Pauls MBA, CEO, Pres & Director (Age 47)
- Dr. Todd A. Verdoorn Ph.D., Chief Scientific Officer
- Mr. Scott B. Kellen, CFO & Company Sec. (Age 53)
- Mr. Edward B. Rady, Chief Commercial Advisor (Age 69)
- Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 48)
Has DiaMedica Therapeutics been receiving favorable news coverage?
Headlines about DMCAF stock have trended positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. DiaMedica Therapeutics earned a coverage optimism score of 0.32 on Accern's scale. They also assigned news stories about the company an impact score of 47.40 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for DiaMedica Therapeutics.
How do I buy shares of DiaMedica Therapeutics?
Shares of DMCAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DiaMedica Therapeutics' stock price today?
One share of DMCAF stock can currently be purchased for approximately $0.3823.
How big of a company is DiaMedica Therapeutics?
DiaMedica Therapeutics has a market capitalization of $64.25 million. DiaMedica Therapeutics employs 7 workers across the globe.
How can I contact DiaMedica Therapeutics?
DiaMedica Therapeutics' mailing address is 2 Carlson Parkway Suite 260, Minneapolis MN, 55447. The company can be reached via phone at 763-496-5454 or via email at [email protected]
MarketBeat Community Rating for DiaMedica Therapeutics (OTCMKTS DMCAF)
MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote "Outperform" if you believe DMCAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMCAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
